Synonyms: NT5E, Ecto-5'-nucleotidase
Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 1 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.
|
References |
|---|
| CAS No. | 1803176-05-7 |
|---|---|
| Molecular Weight | 143.14 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05061550 | RECRUITING | Drug: Durvalumab|Drug: Oleclumab|Drug: Monalizumab|Drug: Dat | Non-small Cell Lung Cancer | AstraZeneca | 2022-04-14 | PHASE2 |
| NCT06984588 | ACTIVE_NOT_RECRUITING | Drug: Uliledlimab|Drug: Toripalimab|Drug: Pembrolizumab | Non Small Cell Lung Cancer | TJ Biopharma Co., Ltd. | 2024-03-28 | PHASE2; PHASE3 |
| NCT07146230 | NOT_YET_RECRUITING | Drug: Durvalumab|Drug: Monalizumab|Drug: Oleclumab | Non-small Cell Lung Cancer | Montefiore Medical Center | 2026-09 | PHASE2 |
| NCT04940286 | ACTIVE_NOT_RECRUITING | Drug: Gemcitabine|Drug: Nab-paclitaxel | Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8 | M.D. Anderson Cancer Center | 2021-09-28 | PHASE2 |
| NCT04668300 | ACTIVE_NOT_RECRUITING | Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma | M.D. Anderson Cancer Center | 2020-11-26 | PHASE2 | |
| NCT07333573 | NOT_YET_RECRUITING | Stage IV Gastric Cancer | Shanghai Zhongshan Hospital | 2026-01-01 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-21)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.